<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103180</url>
  </required_header>
  <id_info>
    <org_study_id>MH084904</org_study_id>
    <nct_id>NCT01103180</nct_id>
  </id_info>
  <brief_title>Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder</brief_title>
  <official_title>SSRIs and Self-harm in Borderline Personality Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Mississippi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to examine the effectiveness the selective serotonin reuptake
      inhibitor (SSRI) escitalopram (also known by the trade name &quot;Lexapro&quot;) in reducing desire to
      self-harm and actual self-harming among young adults with borderline personality disorder who
      are also currently depressed. Subjects will receive either escitalopram or placebo for eight
      weeks. During this time subjects will be make weekly visits to see the psychiatrist and
      record their thoughts and feelings several times each day using an electronic diary.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>self-harm ideation</measure>
    <time_frame>pretreatment to 1-week post treatment</time_frame>
    <description>Self-harm ideation will be assessed using electronic diaries throught the trial from one week pre-treatment to one week post-treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>pre-treatment to 1 week post-treatment</time_frame>
    <description>depressive symptoms will be assessed using weekly interviews and electronic diaries throught the trial from one week pre-treatment to one week post-treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert placebo (sugar pill) taken daily for eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Borderline Personality Disorder

          -  Current Major Depression

        Exclusion Criteria:

          -  Past 2 months SSRI use

          -  Past 6 months non-SSRI antidepressant use

          -  Past 2 months initiation of psychotherapy

          -  Lifetime bipolar disorder, organic disorder, psychotic disorder

          -  Current alcohol or drug dependence

          -  Current severe suicidal / homicidal ideation necessitating immediate medical
             intervention

          -  Currently pregnancy or nursing

          -  Unable or unwilling to cooperate with study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S McCloskey, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University (primary) / University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emil F Coccaro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selective Serotonin Reuptake Inhibitor</keyword>
  <keyword>Escitalopram</keyword>
  <keyword>Borderline Personality Disorder</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Self-harm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 24, 2017</submitted>
    <returned>August 25, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

